Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices 45057 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

www.ninds.nih.gov, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Baswis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: August 3, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3902 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel, Executive Function. 

Date: August 22, 2007. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Richard D. Crosland, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, Division of Extramural 

Research, NINDS/DHHS/Neuroscience 

Center, 6001 Executive Blvd., Suite 3208, 

MSC 9529, Bethesda, MD 20892–9529, 301–

594–0635, rc218u@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: August 2, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3903 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center For Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Renal and Urological 

Studies Integrated Review Group, Urologic 

and Kidney Development and Genitourinary 

Diseases Study Section. 

Date: September 10–11, 2007. 

Time: 8 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crowne Plaza–Silver Spring, 8777 

Georgia Avenue, Silver Spring, MD 20910. 

Contact Person: Daniel F. McDonald, Phd, 

Scientific Review Administrator, Chief, 

MOSS IRG, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 4214, MSC 7814, Bethesda, MD 

20892, (301) 435–1215, 

mcdonald@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group, 

Oral, Dental and Craniofacial Sciences Study 

Section. 

Date: September 13–14, 2007. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Tamizchelvi Thyagarajan, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4016K, 

MSC 7814, Bethesda, MD 20892, 301–451–

1327, tthyagar@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Bridges to 

the Future. 

Date: September 14, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Beacon Hotel and Corporate 

Quarters, 1615 Rhode Island Avenue, NW., 

Washington, DC 20036. 

Contact Person: Cathleen L. Cooper, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4208, 

MSC 7812, Bethesda, MD 20892, 301–435–

3566, cooperc@csr.nih.gov. 

Name of Committee: Oncological Sciences 

Integrated Review Group, Cancer Molecular 

Pathobiology Study Section. 

Date: September 17–18, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Alexandria Old Town, 1767 

King Street, Alexandria, VA 22314. 

Contact Person: Elaine Sierra-Rivera, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

MSC 7804, Bethesda, MD 20892, 301–435–

1779, riverase@csr.nih.gov. 

Name of Committee: Oncological Sciences 

Integrated Review Group, Cancer 

Immunopathology and Immunotherapy 

Study Section. 

Date: September 20–21, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Plaza Hotel, 10 Thomas 

Circle, NW., Washington, DC 20005. 

Contact Person: Steven B. Scholnick, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6152, 

MSC 7804, Bethesda, MD 20892, 301–435–

1719, scholnis@csr.nih.gov. 

Name of Committee: Immunology 

Integrated Review Group, Transplantation, 

Tolerance, and Tumor Immunology Study 

Section. 

Date: September 24–25, 2007. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Fairmont Washington, DC, 2401 

M Street, NW., Washington, DC 20037. 

Contact Person: Cathleen L. Cooper, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4208, 

MSC 7812, Bethesda, MD 20892, 301–435–

3566, cooperc@csr.nih.gov. 

Name of Committee: Oncological Sciences 

Integrated Review Group, Basic Mechanisms 

of Cancer Therapeutics Study Section. 

Date: September 24–25, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 


sroberts on PROD1PC70 with PROPOSALS
45058 Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices 

Place: Miyako Hotel, 1625 Post Street, San 

Francisco, CA 94115. 

Contact Person: Suzanne L. ForrySchaudies, PhD, Scientific Review 

Administrator, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 6192, MSC 7804, Bethesda, MD 

20892, 301–451–0131, forryscs@csr.nih.gov. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group, 

Integrative and Clinical Endocrinology and 

Reproduction Study Section. 

Date: September 26–27, 2007. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Michael Knecht, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6176, 

MSC 7892, Bethesda, MD 20892, 301–435–

1046, knechtm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, AcademicIndustrial Partnership for Cancer Imaging. 

Date: September 28, 2007. 

Time: 11 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Xiang-Ning Li, MD, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5112, 

MSC 7854, Bethesda, MD 20892, 301–435–

1744, lixiang@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research; 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: August 2, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3898 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Method for Treating Strokes 

by Inducing Tolerance to E-Selectin 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license worldwide to practice the 

inventions embodied in: U.S. Patent 

Application Numbers 60/206,693 filed 

May 24, 2000, 10/296,423 filed 

November 22, 2002 and corresponding 

foreign applications entitled ‘‘Method 

for Preventing Strokes by Inducing 

Tolerance to E-Selectin’’ and U.S. Patent 

Application Numbers 60/828,732 filed 

October 9, 2006 and 60/905,741 filed 

March 8, 2007 entitled ‘‘Treatment and 

Prevention of Inflammation’’ to 

Novavax, Inc., having a place of 

business in Rockville, Maryland. The 

patent rights in these inventions have 

been assigned to the United States of 

America. 

The contemplated exclusive license 

may be limited to the use of E-selectin 

for the prevention or treatment of stroke. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

October 9, 2007 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Norbert J. Pontzer, J.D., PhD, 

Technology Licensing Specialist, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435–

5502; Facsimile: (301) 402–0220, E-mail: 

pontzern@mail.nih.gov. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent application if not yet published. 

SUPPLEMENTARY INFORMATION: This 

invention provides methods of treating 

or preventing brain damage in stroke 

through administration of E-selectin, an 

inducible adhesion molecule on 

endothelial cells. The expression of 

E-selectin is induced on human 

endothelium in response to activation 

by cytokines IL–1 and TNF. E-selectin 

mediates the adhesion of various 

leukocytes, including neutrophils, 

monocytes, eosinophils, natural killer 

cells, and a subset of T cells to activated 

endothelium. Activation of vascular 

endothelial cells by proinflammatory 

cytokines is believed to be involved in 

conversion of the luminal surface of 

endothelium from anticoagulant and 

anti-inflammatory to procoagulant and 

pro-inflammatory leading to thrombosis. 

Segmental vascular activation and 

thrombosis are involved in the 

development of strokes. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: August 3, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–15621 Filed 8–9–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Musculoskeletal Rehabilitation. 

Date: August 16, 2007. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Jo Pelham, BA, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 4102, MSC 7814, 

Bethesda, MD 20892, (301) 435–1786, 

pelhamj@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 


sroberts on PROD1PC70 with PROPOSALS